The biopharma world is here. Get the industry’s most comprehensive daily news reports at endpts.com/subscribe
Global
- Tweets 50,522
- Following 80
- Followers 31,911
- Likes 4,442
What kind of biotech startup wins a $3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain
endpts.com/what-kind-of-biot…
34
131
🚨 The FDA's Peter Marks has resigned, after disagreeing with HHS Secretary Robert F. Kennedy Jr. over Kennedy's anti-vaccine policies.
In a scathing letter, Marks criticized Kennedy for what he called "misinformation and lies"
endpts.com/fdas-peter-marks-…
11
37
114
70,618
🚨 BREAKING: Vinay Prasad, FDA's controversial head of vaccines and biologics, is out
endpoints.news/vinay-prasad-…
13
23
92
44,734
Exclusive: Vertex is pulling back on its genetic medicine research, ending all work related to adeno-associated viruses, or AAVs endpts.com/vertex-drops-aav-…
3
16
86
24,735
Last month, DeepMind released a specialized version of the original AlphaFold software for predicting protein-protein complexes. The new approach could help unlock insights into the underlying process behind a wide range of diseases.
endpts.com/its-a-transformat…
2
13
77
Scott Gottlieb on what it would take to compete with China's biotech rise nitter.app/i/broadcasts/1nAKEEony…
5
7
15
43,680
For the first time, completely designed — or “de novo,” meaning from the beginning — proteins are being tested in clinical trials, perhaps most notably as a cancer immunotherapy invented in David Baker’s lab and developed by a spinout.
endpts.com/scientists-are-fi…
1
13
67
Arcadia will study a selection of so-called non-model organisms: the literally trillions of organisms that are rarely studied in labs because they’re difficult to manipulate or don’t obviously translate to humans.
endpts.com/can-this-tick-bio…
2
5
60
Just a few short months after Altos Labs made its debut flush with $3 billion in cash, a famous CEO and a star-studded scientific team, the cellular rejuvenation biotech may now be seeing the first inklings of a competitor: Genentech.
endpts.com/an-altos-labs-riv…
2
19
63
David Liu, the co-inventor of base editing and co-founder of Beam Therapeutics, unveiled a new approach for using CRISPR to turn patients’ sickling hemoglobin into a healthy form of the protein.
endpts.com/relying-on-an-obs…
17
64
Vertex and CRISPR Therapeutics showed their experimental therapy kept two sickle patients from experiencing painful incidences and kept patients with another blood disorder from requiring transfusions.
endpts.com/vertex-looking-to…
3
13
62
Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion.
endpts.com/novartis-buys-kat…
2
18
55
46,952
Breaking: In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia endpts.com/uk-approves-verte…
1
5
53
17,892
During #DrugDiscoveryDay @RLCscienceboss had an in-depth discussion with @arenabioworks co-founder @SchreiberStuart around small molecule drug discovery, AI in chemical biology, & new models of funding science. Watch this conversation & more On Demand: bit.ly/44503Ak
1
15
54
30,992
Bezos, Paul Allen funds, a16z put up $100M to build an Illumina of human proteins endpts.com/bezos-paul-allen-…
14
49
🚨 EXCLUSIVE: Illumina CEO Francis deSouza has resigned, just weeks after activist investor Carl Icahn waged an unsuccessful battle to remove him from the board
endpts.com/exclusive-illumin…
3
23
47
83,098
Craig Crews-founded startup Halda Therapeutics raises $76 million with hopes to create new cancer medicines
endpts.com/protacs-to-riptac…
6
41
5,492
Armed with positive ALS data, Amylyx scores $30M in fresh funding to complete Alzheimer's PhII endpts.com/armed-with-positi…
3
17
44
Samsung Biologics already has three plants in Songdo, Incheon, South Korea, and another on the way — and it just gained approval to build a fifth.
endpts.com/as-2b-superplant-…
2
4
47
For a second year in a row, we’ve launched a 20 under 40 project and arrived, months later, with a list of 21 names. Learn more about the next generation of biotech leaders in this year's 20(+1) under 40 feature:
endpts.com/the-201-under-40-…
9
42
Genentech will pay $50 million upfront and a potential $620 million in milestones for licensing rights to Lineage Cell Therapeutics’ OpRegen program, a cell therapy that aims to regenerate healthy versions of retinal pigment epithelial cells in the eyes.
endpts.com/roche-genentech-t…
2
10
43
President Joe Biden early Monday unveiled his intent to appoint Renee Wegrzyn, VP of business development at Ginkgo Bioworks, as the first director of the Advanced Research Projects Agency for Health (ARPA-H).
endpts.com/biden-turns-to-bi…
2
13
39
Humanigen, the one-time Martin Shkreli-run biotech, announced that its antibody helped keep patients with #Covid19 off ventilation in a Phase III trial, potentially giving doctors just their second proven tool for helping patients with severe disease.
endpts.com/humanigen-declare…
6
37
We are shocked and saddened to learn of the death of Endpoints alum Natalie Grover, who was a part of the newsroom from 2018 to 2020 and went on to a great career at Reuters.
Our deepest condolences to her family and loved ones.
My daughter, Natalie Grover, died in a road accident on June 14 in Ealing, London. We traveled from India but have no info about her body or post-mortem. The liaison officer hasn't helped. It’s been 5 days. We want to perform her last rites.
@RishiSunak @HCI_London @ReutersUK
1
10
35
12,595
Vilya, which got its name from The Lord of the Rings, is starting out with a $50 million Series A. The name was suggested by IPD’s science communication manager Ian Haydon, since Vilya is one of the rings in Tolkien mythology known for its power to heal.
endpts.com/david-bakers-lab-…
1
9
38
FDA update: Staff who've witnessed this morning's scene at the agency headquarters described it as a "bloodbath". The firings include whole offices at the regulator, multiple FDA sources told Endpoints, including leadership and administrative staff in several departments.
endpts.com/firings-sweep-acr…
1
15
35
10,655
Merck is linking arms with Ginkgo Bioworks to help boost active pharmaceutical ingredient production through the use of enzymes.
endpts.com/ginkgo-inks-144m-…
6
31
One night last fall, Floris Engelhardt sat down in her Boston apartment and logged onto a Zoom call, armed with a comic and a vague idea about starting a biotech.
endpts.com/george-church-his…
1
16
35
A group of powerhouse biotech leaders is coming together to launch a new nonprofit, one aimed at delivering therapies to rare disease populations they believe pharma is leaving behind.
endpts.com/scoop-inspired-by…
1
5
30
Top lead cancer drug researcher Alice Shaw bids adieu to academia, hello to Novartis endpts.com/top-lead-cancer-d…
2
7
29
Raising money? Links to all 100 top biotech VC firms here: endpts.com/special/where-the…
Top 25 by total invested in 2016 👇🏽
21
28
On this #RareDiseaseDay, let’s all commit to helping recognize the life and work of #biotech giant Henri A. Termeer endpts.com/on-this-rare-dise… #RareDiseaseDay2018
20
27
After two and a half decades of fitful starts and abandoned leads, Thomas Braun and a team of researchers at the Max Planck Institute showed they could reprogram heart cells in mice and get the animals to regenerate cardiac tissue after a heart attack.
endpts.com/in-step-forward-f…
7
30
Exclusive: Biogen will cut jobs in its research unit to refocus on external opportunities and a streamlined preclinical portfolio, aiming for faster proof-of-concept in trials. endpts.com/exclusive-biogen-…
2
10
26
24,775
Adeno-associated viruses can only carry a transgene up to a certain size. But what if you can deliver the full gene in two parts? SpliceBio has raised close to $57 million (€50 million) to test the concept.
endpts.com/some-genes-are-to…
3
24
Verve Therapeutics has dosed the first patient with its lead cardiovascular drug, marking a major milestone for the next-gen gene editing technique known as base editing.
endpts.com/gene-editing-for-…
5
30
Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond endpts.com/special-report-tw…
1
29
Ambagon Therapeutics launched Friday with an $85 million A round and a world-class group of researcher-founders building what are known as “molecular glues” to crack the code on a class of elusive cellular proteins, the biotech said.
endpts.com/a-new-startup-thi…
5
26
ARCH, known for periodically launching massive companies from scratch, announced the creation of Neumora, a biotech its partners believe can finally crack a set of well-known neurodegenerative and psychiatric diseases that have long eluded drugmakers.
endpts.com/arch-unveils-its-…
5
27
Meet 20 extraordinary women who are supercharging biopharma R&D in this year's Women in Biopharma special report, curated by Endpoints' very own @AmberTongPW and @Nicole_DeFeudis!
endpts.com/special-report-20…
1
6
26
Catalent has entered a partnership with a cell therapy company that focuses on neurodegenerative diseases, taking on a tech transfer to manufacture treatments for ALS and PMS.
endpts.com/ever-optimistic-d…
12
7
23
WuXi AppTec reportedly transferred a US client’s intellectual property to Chinese authorities, American intelligence officials told Congress in February. endpts.com/us-intelligence-o…
2
6
20
18,358
Bristol Myers Squibb commits to $300 million to combating racial inequity endpts.com/bristol-myers-squ…
5
25
The IPO market continues to churn, with a prominent AI drug developer becoming the latest biotech to register with the SEC.
endpts.com/recursion-will-ta…
5
26
The stem cell-derived therapy at the center of Vertex’s $950 million buyout of Semma Therapeutics in 2019, one that features prominently in the company’s overall cell and gene therapy push, is one step closer to reaching the clinic.
endpts.com/the-diabetes-cure…
5
24
Ginkgo Bioworks execs always thought big. But today should redefine just how big an upstart biotech player can dream.
endpts.com/ginkgo-bioworks-r…
3
24
CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments endpts.com/cf-foundation-lon…
5
19
🚨 Pharma CEOs are expected to meet with Trump next week at the White House endpts.com/drugmakers-plan-t…
4
4
22
11,509
PacBio was once Illumina's acquisition target. Now it's become a competitor.
@Jared_Whitlock reports on how the sequencing market is evolving:
endpts.com/pacbio-once-slate…
1
8
24
6,135
Don't Blame Silicon Valley for Theranos nytimes.com/2016/04/27/opini… [h/t @bradloncar]
6
23
GSK will chip in on producing Novavax’s recombinant #Covid19 vaccine, pledging fill-finish capacity for 60 million doses of the shot for use in the UK.
endpts.com/glaxosmithkline-o…
4
22
BREAKING: J&J is acquiring Intra-Cellular Therapies for $14.6 billion in the biggest biotech M&A transaction since 2023.
endpts.com/jj-buys-intra-cel…
1
5
23
7,958
GSK has tapped Sosei Heptares for discovery work targeting IBD and other gastrointestinal immune disorders with small-molecule agonists for GPR35, an orphan G protein-coupled receptor (GPCR) with a genetic link to those conditions.
endpts.com/glaxosmithkline-j…
7
22
A new oncology drug endpoint, based on what’s known as minimal residual disease, gained the backing of FDA advisors, potentially opening the door to new trial designs for blood cancer drugs. endpts.com/adcomm-backs-use-…
6
21
7,430
Tiny startup Nabla Bio posted a preprint Thursday highlighting its progress in creating antibodies from scratch that look therapeutically viable against some hard-to-drug targets in what it’s calling a first for the field.
endpts.com/nabla-bio-moves-c…
9
24
2,369
Novartis drums up anticipation for blockbuster-to-be with PhII data on asthma drug endpts.com/novartis-drums-up…
3
23
Congratulations to our #WIB21 honoree @reshmapshetty, co-founder of @Ginkgo. Now valued at more than $15 billion, Shetty and the team at Ginkgo are working on tools to reprogram cells at scale, just as one might debug a computer program.
endpts.com/special-report-me…
5
23
Process engineer in biopharma? Learn how scientists are using new tech to master cell culture harvests in this webinar from 3M. webinars.endpts.com/reinvent…
4
21
Gilead’s remdesivir — or Veklury, as it’s marketed in the US — raked in around $2.8 billion last year as the only FDA-approved antiviral to treat Covid-19. But new data from a European study suggest the drug has no actual benefit.
endpts.com/european-study-fi…
3
6
21
Soufflé Therapeutics, co-founded by Bob Langer, launched with $200M to develop targeted genetic medicines for muscle, heart, and metabolic diseases. endpoints.news/souffle-thera…
2
4
20
6,074
CRISPR pioneer Feng Zhang launches a ‘limitless’ biotech upstart with big plans for speeding new drug development endpts.com/crispr-pioneer-fe… #CRISPR #startup
13
22
Biopharma M&A appears to be having a bit of a bump:
March 13: Pfizer-Seagen ($43B)
March 14: Sanofi-Provention ($2.9B)
April 17: Merck-Prometheus ($10.8B)
Today: GSK-Bellus ($2B)
endpts.com/gsk-acquires-bell…
3
22
7,187
Alnylam appears to have won a highly anticipated approval for its drug Amvuttra to treat ATTR-CM, according to a drug label posted online: endpts.com/alnylam-appears-t… $ALNY
2
19
4,027
Jennifer Lawrence will star in a movie about Theranos theverge.com/2016/6/9/118965… [h/t @sesiegler]
3
17
20
AstraZeneca gets in on RNA game with MiNA research collaboration endpts.com/astrazeneca-gets-…
10
22
The biggest of Big Pharma is turning over a new, edgier leaf, proposing to spend $500,000 to join a new cooperative, known as VitaDAO, for community-governed and decentralized drug development focused on extending human life.
endpts.com/pfizer-buys-into-…
10
19
Eli Lilly's Jake Van Naarden uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million — $300 million in cash and $80 million for a premium equity deal — to jump on board the biotech’s development platform.
endpts.com/eli-lillys-van-na…
7
21
WATCH: @JohnCendpts breaks down the drug pricing issue at #JPM17
14
22
Hats off to @mammothbiosci. Nobody knows better how important CRISPR/Cas9 has been to the gene editing field. And no one knows better than the folks running this Jennifer Doudna startup just how much the field still needs to be developed.
endpts.com/the-endpoints-11-…
7
22
Alltrna launched Tuesday with $50 million in funding from Flagship and years of work behind the scenes building expertise from scratch in adapting learnings from inside the cell into a growing therapeutic platform based around tRNA biology.
endpts.com/a-new-flagship-st…
1
3
20
Ginkgo Bioworks is acquiring and distributing 50 million rapid antigen tests that can potentially be used for #Covid19 surveillance in schools and communities and for quick, on the ground diagnoses.
endpts.com/exclusive-eyeing-…
5
19
Allergan and Gedeon Richter ready to knock on FDA’s door after a positive PhIII for cariprazine in #bipolar #depression endpts.com/allergan-and-gede…
6
21
Why @ScottGottliebMD, venture capitalist, sees opportunity in antibiotics endpts.com/why-scott-gottlie…
1
6
18
Boundless Bio CEO Zach Hornby and his team emerged today with a $105 million Series B led by Nextech Invest and RA Capital Management and plans to be in the clinic by 2023.
endpts.com/boundless-bio-rai…
7
20
Pfizer’s former CSO Mikael Dolsten and Yale’s Craig Crews have launched Quarry Thera, a new biotech developing next-gen molecular glue therapeutics. endpoints.news/mikael-dolste…
3
21
10,326
With backing from Third Rock and a clutch of A-list biotech VCs on board, Septerna Therapeutics launched with $100 million, an already bustling pipeline and new technology offering researchers their best-ever look at the function and shape of GPCRs.
endpts.com/a-new-third-rock-…
8
19
Novo Nordisk pulled a highly anticipated win for its GLP-1 therapy semaglutide in obesity on Friday, becoming the first company to get a chronic weight management drug for adults past regulators since 2014.
endpts.com/novo-nordisk-scor…
1
4
21
For a second year in a row, we’ve launched a 20 under 40 project and arrived, months later, with a list of 21 names. Learn more about the next generation of biotech leaders in this year's 20(+1) under 40 feature:
endpts.com/the-201-under-40-…
1
21
UPDATED: Bluebird’s one-shot gene therapy for #betathalassemia officially secures #EMA backing — approval expected in the second quarter endpts.com/bluebirds-one-sho…
1
7
17
Google’s GV enlists machine learning pro Rosana Kapeller in its drive to create a new breed of biotech endpts.com/googles-gv-enlist…
9
18
#FDA will allow observational studies as part of a push for real world evidence, new framework says endpts.com/fda-will-allow-ob… via @rapsorg
3
14
17
The latest Jennifer Doudna startup launches with a Biogen partnership and eyes on big targets few CRISPR companies have chased endpts.com/the-latest-jennif…
1
8
19
BREAKING: Novo Nordisk's CagriSema fails to hit 25% weightloss benchmark in Phase 3 readout. Novo’s stock $NVO crashed by as much as 26% pre-market Friday.
endpts.com/novo-reveals-23-w…
2
4
17
48,668
🚨 Bristol Myers makes a $4.8B bet on KRAS, striking deal to acquire Mirati
endpts.com/bristol-myers-to-…
6
15
6,245
The FDA on Tuesday granted accelerated approval to Johnson & Johnson’s Tecvayli (teclistamab), a BCMA-directed bispecific antibody, looking to head into an already crowded field of treatments aiming to help those with the blood cancer multiple myeloma.
endpts.com/fda-approves-jjs-…
3
8
Who makes up the next generation of biotech leaders? For the first time, we've included two dual profiles in our annual 20-under-40 project, resulting in a list of 21 young leaders whose stories are crucial to understanding the industry today.
endpts.com/the-201-under-40-…
1
4
19
Datavant boots up a big Covid-19 registry — looking to shine a light on virus spread, impact and most effective therapies endpts.com/datavant-launches…
3
12
15
The FDA’s ODAC nearly unanimously recommended against approving Eli Lilly and Innovent’s anti-PD-1 antibody sintilimab, dealing a blow to “me too” cancer drugmakers hoping to reach the market based solely on data from China.
endpts.com/breaking-fda-advi…
2
4
19
How do we put the AI in R&D in a real world way with all the practical parameters eg budget? @JohnCendpts kicks off panel discussion at #BIO2019
2
4
19
The effects of BioMarin’s vaunted gene therapy for hemophilia A are continuing to fade in the earliest treated patients, renewing questions about the long-term prospects for a drug the company had billed as a one-time cure.
endpts.com/new-data-show-bio…
7
18
Most artificial intelligence biotechs start with a computer scientist or two and an algorithm. Jen Nwankwo started from the other side of the spectrum.
endpts.com/exclusive-microso…
5
16
With a slew of pricey oncology drugs dominating the market, disruptor EQRx has pledged to launch its own discounted competitors to bring the fight to Big Pharma’s pocketbook.
endpts.com/eqrxs-cheaper-egf…
4
17
JP Morgan isn’t typically a data conference. But there are always exceptions for data that could make or break a company, like what Sekar Kathiresan is bringing to the virtual conference.
endpts.com/looking-to-leapfr…
4
19
Lilly hired Denali’s Carole Ho to lead neuroscience and promoted Adrienne Brown to head immunology, while expanding roles for top execs. endpoints.news/lilly-hires-d…
17
3,341
👀A week before she won the Nobel Prize, Katalin Karikó spoke with @RLCscienceboss for an hour about her career, her work on mRNA, being rejected and then finally recognized at the highest level.
A must-read conversation:
endpts.com/qa-nobel-prize-wi…
1
4
17
6,401
Remember 2022 as a critical year for base editing, David Liu tells @ZacharyBrennan.
The Broad Institute professor talks safety, CRISPR vs. prime and base editing, costs of and access to gene editing, R&D speed and minting founders in his lab
endpts.com/interview-with-th…
5
16
'Tremendous' animal data inspire GV, ARCH's $63M booster for Sekar Kathiresan's drive to relegate chronic heart disease to history endpts.com/tremendous-animal…
4
15
AstraZeneca names controversial cancer scientist José Baselga to a top R&D post in major shakeup endpts.com/astrazeneca-names…
4
14
“Cell therapies have had an enormous impact on blood cancers, but effectively targeting solid tumors remains one of the holy grails in biotech,” Endpoints founder John Carroll said. One of our #endpts11 winners has taken on the challenge. Read more about them in our story coming out tomorrow.
2
17
5,262
Pioneering regenerative med scientist Laura Niklason takes her company public in the latest big SPAC deal. And that gives her a shot at making biotech history endpts.com/pioneering-regene…
5
18